Oversight Committee Hearing on FDA Regulations and Crises Management

Regulations by 2FIRSTS.ai
Apr.09.2024
Oversight Committee Hearing on FDA Regulations and Crises Management
The House Oversight Committee will hold a hearing on FDA oversight with Director Robert Califf amid multiple crises.

According to the official website of the U.S. House of Representatives, the House Committee on Oversight and Reform will hold a hearing this week titled "Oversight of the Food and Drug Administration." Robert Califf, the Commissioner of the Food and Drug Administration, will testify and answer questions about the agency's regulation of tobacco and nicotine products.

 

The purpose of this hearing is to review the ongoing investigations by the oversight committee into the FDA's handling of various issues, including the infant formula crisis, food safety, drug shortages, facility inspections, cannabis regulation, tobacco and nicotine product regulation, as well as over-the-counter decongestants.

 

The oversight committee emphasized several crises that have occurred within the FDA's regulatory scope, pointing out that these events have had a negative impact on the lives and health of American citizens and families. Chairman of the oversight committee, James Comer, stated that they will be requesting the FDA Commissioner to explain the actions taken in response to the current crises, inspection measures to prevent nationwide crises in the future, and steps to ensure the primary protection of American consumers.

 

The hearing will be held on Thursday, April 11, 2024 at 1:00 PM Eastern Time, with witnesses including FDA Commissioner Dr. Robert Califf. The hearing will be open to the public and media, and will be live-streamed on https://oversight.house.gov/.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA to Review Philip Morris International’s IQOS Risk Modification Renewal Application in October
U.S. FDA to Review Philip Morris International’s IQOS Risk Modification Renewal Application in October
The U.S. FDA will review Philip Morris International’s renewal application for five IQOS products' modified risk status at an October 7 TPSAC meeting, evaluating whether they still meet the required standards.
Jul.30 by 2FIRSTS.ai
Glo Hilo goes nationwide in Japan, 2Firsts tracks market feedback: flavor and appearance are well-received, but price is a point of contention.
Glo Hilo goes nationwide in Japan, 2Firsts tracks market feedback: flavor and appearance are well-received, but price is a point of contention.
BAT Japan launched a new heated tobacco product, glo Hilo, on September 1st. Priced at 3,980 yen, it received positive initial feedback. Users praised its stylish design and better taste and odor control compared to IQOS. The main criticism was a burnt taste on the first puff due to rapid heating.
Sep.02
Nigerian Group Calls for 100% Increase in Tobacco Tax to Cut Health Costs
Nigerian Group Calls for 100% Increase in Tobacco Tax to Cut Health Costs
CAPPA urges Nigerian government to increase tobacco tax to 100% to save lives and cut healthcare costs.
Aug.08 by 2FIRSTS.ai
U.S. Fourth Circuit Court Rules North Carolina Can Ban Sale of FDA-Unapproved E-Cigarette Products
U.S. Fourth Circuit Court Rules North Carolina Can Ban Sale of FDA-Unapproved E-Cigarette Products
The U.S. Fourth Circuit Court upheld North Carolina's right to ban the sale of FDA-unapproved e-cigarettes, rejecting an injunction request. Plaintiffs argued the state can't enforce FDA rules, but the state said halting the law would cause confusion. The case remains under review.
Jul.30 by 2FIRSTS.ai
China Tobacco Hong Kong 2025 Interim Results: Revenue HKD 10.3 billion, up 18.5% year-on-year; New Tobacco Export Business Revenue HKD 14.6 million, down 66.5% year-on-year
China Tobacco Hong Kong 2025 Interim Results: Revenue HKD 10.3 billion, up 18.5% year-on-year; New Tobacco Export Business Revenue HKD 14.6 million, down 66.5% year-on-year
China Tobacco International (Hong Kong) recorded revenue of HKD 10.32 billion in the first half of 2025, up 18.5% year-on-year, with gross profit down 1.8%. Net profit attributable to shareholders was HKD 706 million, up 9.8% year-on-year. Revenue from the new tobacco export business was HKD 14.6 million, down 66.5% year-on-year.
Aug.22 by 2FIRSTS.ai
Company | Itsuwa Technology to Establish French Subsidiary to Boost Overseas Footprint; 2024 Net Profit Down 194.47% YoY
Company | Itsuwa Technology to Establish French Subsidiary to Boost Overseas Footprint; 2024 Net Profit Down 194.47% YoY
Itsuwa Technology announced that it plans to establish a wholly owned subsidiary in Paris, France—ITSUWA FRANCE—with a registered capital of €10,000, to engage in promotion, marketing activities, and brand management. In 2024, the company’s revenue fell 12.59% to RMB 283 million, and it recorded a net loss of RMB 19.66 million. The investment aims to strengthen overseas presence and enhance brand and market responsiveness.
Sep.12 by 2FIRSTS.ai